tiprankstipranks
Trending News
More News >
Advertisement

HFXI - ETF AI Analysis

Compare

Top Page

HFXI

IQ 50 Percent Hedged FTSE International ETF (HFXI)

Rating:61Neutral
Price Target:
HFXI, the IQ 50 Percent Hedged FTSE International ETF, has a solid but not top-tier rating, driven largely by high-quality global leaders like Novartis, AstraZeneca, HSBC, Toyota, and ASML, which show strong financial performance, positive earnings outlooks, and generally supportive valuations. The rating is held back somewhat by holdings such as Shell and Commonwealth Bank of Australia, where technical weakness, valuation concerns, and cash flow or leverage issues introduce added risk. A key risk factor is the fund’s meaningful exposure to a mix of financials, healthcare, and energy names where overvaluation or short-term technical pressures could weigh on returns.
Positive Factors
Broad International Diversification
The fund spreads its investments across many countries like Japan, the UK, France, and Germany, which helps reduce the impact of problems in any single market.
Balanced Sector Mix
Holdings are spread across financials, industrials, health care, technology, and several other sectors, helping avoid heavy dependence on just one part of the economy.
Competitive Expense Ratio
The ETF’s relatively low expense ratio means less of your return is lost to fees each year.
Negative Factors
Moderate Country Concentration
A sizable portion of assets is concentrated in a few markets like Japan and the UK, which can hurt returns if those economies struggle.
Mixed Performance Among Top Holdings
While some leading positions like ASML, Toyota, and Siemens have shown strong gains, others such as SAP, Nestlé, AstraZeneca, and Shell have been weaker, creating uneven support for the fund.
Limited U.S. Exposure
The fund has only a small allocation to U.S. stocks, so investors relying on U.S. market strength will not get much benefit from this ETF alone.

HFXI vs. SPDR S&P 500 ETF (SPY)

HFXI Summary

HFXI is an ETF that follows the FTSE Developed ex North America 50% Hedged to USD Index, giving you broad exposure to stocks in developed countries like Japan, the UK, and Europe while partially reducing currency swings versus the U.S. dollar. It owns many large, well-known companies such as Toyota, Nestlé, and AstraZeneca across sectors like financials, industrials, and healthcare. Someone might invest in HFXI to diversify beyond the U.S. and seek long-term growth from international markets with some currency protection. A key risk is that international stock prices can still go up and down significantly with global markets.
How much will it cost me?The IQ 50 Percent Hedged FTSE International ETF (HFXI) has an expense ratio of 0.20%, which means you’ll pay $2 per year for every $1,000 invested. This is lower than average because it is passively managed, tracking an index rather than relying on active stock picking.
What would affect this ETF?HFXI could benefit from growth in developed international markets, especially if sectors like financials and technology perform well, as they are heavily weighted in the ETF. However, potential risks include economic slowdowns in Europe or Asia, regulatory changes affecting top holdings like ASML and Nestlé, and adverse currency movements despite partial hedging. Global interest rate changes and geopolitical tensions could also impact the ETF's performance.

HFXI Top 10 Holdings

HFXI leans heavily on a mix of European and Asia-Pacific blue chips, with health care and financial giants setting the tone. Drugmakers like Roche, Novartis, and AstraZeneca have been steadily rising, giving the fund a solid defensive backbone, while Nestlé adds a slow-and-steady consumer tilt. On the financial side, HSBC and Commonwealth Bank of Australia are helping, not hurting, as global banks regain their footing. ASML and Siemens bring an industrial and tech edge, though Siemens has been more mixed lately, slightly tapping the brakes on otherwise broad-based developed-market gains outside North America.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
ASML Holding NV2.24%$31.21M€475.49B74.46%
76
Outperform
Roche Holding AG1.34%$18.68MCHF294.84B46.01%
73
Outperform
Novartis AG1.21%$16.93MCHF242.43B28.84%
80
Outperform
AstraZeneca1.19%$16.53M$323.92B30.42%
80
Outperform
HSBC Holdings1.15%$16.09M£222.90B45.63%
80
Outperform
Nestlé SA1.02%$14.15MCHF198.29B10.92%
71
Outperform
Toyota Motor0.98%$13.64M¥48.61T34.33%
80
Outperform
Shell (UK)0.89%$12.38M£165.51B11.49%
73
Outperform
Commonwealth Bank of Australia0.84%$11.76MAU$295.71B18.41%
64
Neutral
Siemens0.83%$11.56M€191.01B9.25%
74
Outperform

HFXI Technical Analysis

Technical Analysis Sentiment
Positive
Last Price
Price Trends
50DMA
33.71
Positive
100DMA
32.41
Positive
200DMA
30.63
Positive
Market Momentum
MACD
0.65
Negative
RSI
76.47
Negative
STOCH
88.09
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For HFXI, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 35.02, equal to the 50-day MA of 33.71, and equal to the 200-day MA of 30.63, indicating a bullish trend. The MACD of 0.65 indicates Negative momentum. The RSI at 76.47 is Negative, neither overbought nor oversold. The STOCH value of 88.09 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HFXI.

HFXI Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$1.39B0.20%
61
Neutral
$8.75B0.35%
65
Neutral
$8.16B0.28%
67
Neutral
$6.42B0.07%
66
Neutral
$5.69B0.20%
62
Neutral
$2.36B0.58%
66
Neutral
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HFXI
IQ 50 Percent Hedged FTSE International ETF
36.14
9.59
36.12%
DBEF
Xtrackers MSCI EAFE Hedged Equity ETF
FENI
Fidelity Enhanced International ETF
BBIN
JPMorgan BetaBuilders International Equity ETF
EFAV
iShares MSCI EAFE Min Vol Factor ETF
IHDG
WisdomTree International Hedged Quality Dividend Growth Fund
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement